Nifty Pharma index extends fall; Lupin hits 52-week low

Sun Pharma, Dr Reddy's Lab, Glenmark Pharma and Lupin were down 3% on NSE

pharma, pharma industry
Govt proposes to bring fixed-dose combinations under price control
SI Reporter Mumbai
Last Updated : Jul 31 2017 | 3:22 PM IST
Shares of pharmaceutical companies continued to trade under pressure with Nifty Pharma index down more than 1% for the third straight trading sessions after firms reported a disappointing set of numbers for the quarter ended June 2017 (Q1FY18).

At 2:57 pm; Nifty Pharma index, the largest loser among sectoral indices, was down 2% as compared to 0.43% rise in the Nifty 50 index. In past three trading sessions, the pharma index slipped 5.6% against 0.36% rise in the benchmark index.

Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Glenmark Pharmaceuticals and Lupin were down up to 3% on the National Stock Exchange (NSE).

Lupin hit a 52-week low of Rs 1,030 in intra-day trade after the company said the US Food and Drug administration (USFDA) completed the prior approval inspection (PAI) of its Aurangabad manufacturing plant with one 483 observation.

"The observation was procedural in nature and corrected during the inspection itself," Lupin said in a statement.

Dr Reddy’s Laboratories was down 3% to Rs 2,387, extending 9% decline in past two trading sessions, after the  company reported disappointing set of numbers in Q1FY18.

The consolidated net profit for the pharmaceutical company more- than-halved to Rs 59 crore in Q1FY18 against Rs 126 crore in the same quarter year ago. Revenue during the quarter under review grew 3% to Rs 3,316 crore from Rs 3,235 crore in year ago quarter.

Analysts on an average had expected profit of Rs 307 crore on revenues of Rs 3,399 crore for the quarter.

“Our first-quarter results have been below expectations. While headwinds in the form of price erosion due to US customer consolidation continue a lower contribution from new product launches in the US and the GST implementation in India also impacted our performance,” Dr Reddy's Co-Chairman and Chief Executive Officer GV Prasad said while announcing Q1 results.

Company 26/07/2017 28/07/2017 29/07/2017 % chg* %chg#
Cipla 575.45 566.10 559.05 -1.2 -2.8
Glaxosmi. Pharma 2491.85 2443.15 2399.75 -1.8 -3.7
Dr Reddy's Labs 2707.35 2464.95 2390.00 -3.0 -11.7
Lupin 1123.60 1063.90 1034.35 -2.8 -7.9
Sun Pharma.Inds. 579.50 550.80 532.00 -3.4 -8.2
Aurobindo Pharma 747.70 723.90 718.70 -0.7 -3.9
Glenmark Pharma. 707.70 717.45 697.10 -2.8 -1.5
Cadila Health. 548.75 545.85 543.90 -0.4 -0.9
Divi's Lab. 678.80 674.30 670.40 -0.6 -1.2
           
Nifty Pharma 10036.8 9672.6 9480.00 -2.0 -5.5
Nifty 50 10020.65 10014.5 10074.65 0.6 0.5
           
LTP : Last traded price on NSE in Rs at 03:07 pm.
* % change over previous close; # % change over July 26, 2017

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story